# Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)

> **NCT06916520** · PHASE4 · RECRUITING · sponsor: **J.P.S Henriques** · enrollment: 300 (estimated)

## Conditions studied

- Coronary Arterial Disease (CAD)
- Percutaneous Coronary Intervention (PCI)

## Interventions

- **DRUG:** Prasugrel 5 mg
- **DRUG:** Dual Antiplatelet (DAPT) Therapy

## Key facts

- **NCT ID:** NCT06916520
- **Lead sponsor:** J.P.S Henriques
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-13
- **Primary completion:** 2026-04
- **Final completion:** 2027-04
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06916520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06916520, "Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT06916520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*